Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia. (Q54611981)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Differential expression of JAK2 and Src kinase genes in response to hydroxyurea treatment in polycythemia vera and essential thrombocythemia (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

polycythemia vera

1 reference

based on heuristic

inferred from title

hydroxycarbamide

1 reference

based on heuristic

inferred from title

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Lourdes Florensa

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Santiago Barrio

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Joaquin Martinez-Lopez

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

6

object named as

Rosa Ayala

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

author name string

Enriqueta Albizua

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Miguel Gallardo

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Inmaculada Rapado

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Ana Jimenez

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Beatriz Sanchez-Espiridion

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Eulalia Puigdecanet

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Blanca Espinet

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Carles Besses

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

publication date

18 February 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

Annals of Hematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

90

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

939-946

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21331593%20AND%20SRC:MED&resulttype=core&format=json

22 January 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Chronic myeloproliferative diseases with and without the Ph chromosome: some unresolved issues.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

In essential thrombocythemia, multiple JAK2-V617F clones are present in most mutant-positive patients: a new disease paradigm.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Mutation in TET2 in myeloid cancers

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Advances in understanding and management of myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Overproduction of the free radical of ribonucleotide reductase in hydroxyurea-resistant mouse fibroblast 3T6 cells

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

High resolution melting analysis for JAK2 Exon 14 and Exon 12 mutations: a diagnostic tool for myeloproliferative neoplasms

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Dasatinib inhibits progenitor cell proliferation from polycythaemia vera

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status

1 reference

https://api.crossref.org/works/10.1007%2FS00277-011-1179-2

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54611981&oldid=2265228425"